Skip to main content

Table 4 Factors associated with a positive MP-specific IgM at the time of admission in children hospitalized due to MP pneumonia

From: Clinical significance of Mycoplasma pneumoniae specific IgM titer in children hospitalized with Mycoplasma pneumoniae pneumonia

Variables OR aORa (95% CI) P value
Age, years 0.926 (0.84–1.02) 3.64 (0.38–34.54) 0.261
Duration between symptom onset and admission, days 1.46 (1.24–1.73) 1.47 (1.24–1.75) < 0.001
Total duration of fever during illness, days 1.16 (1.03–1.30) 1.15 (1.02–1.30) 0.019
Total hospitalization duration, days 1.09 (0.99–1.19) 1.08 (0.98–1.18) 0.107
Development of any extra-pulmonary symptoms 7.08 (1.61–31.10) 9.16 (1.96–42.81) 0.005
Hemoptysis 0.10 (0.01–0.96) 0.13 (0.01–1.45) 0.097
White blood cells, /µL 1.23 (1.07–1.40) 1.23 (1.07–1.41) 0.003
Serum lactate dehydrogenase, IU/L 1.00 (1.00-1.01) 1.00 (1.00-1.01) 0.001
Serum albumin, g/dL 1.07 (0.83–1.37) 1.08 (0.84–1.39) 0.558
Respiratory virus co-infection, yes, n (%) 1.70 (0.78–3.70) 1.36 (0.59–3.14) 0.466
Positive results on pneumobacter PCR except MP, n (%) 0.56 (0.16–1.96) 0.47 (0.11–1.98) 0.301
Respiratory virus co-infection or positive results on pneumobacter PCR except MP, n (%) 1.62 (0.77–3.44) 1.40 (0.63–3.10) 0.414
Response to stepwise treatment in MP pneumonia
 Good response Ref Ref  
 Poor responseb 2.06 (0.97–4.35) 1.87 (0.84–4.18) 0.128
Severity of MP pneumonia based on the extent of pneumonic lesion on chest radiography at the time of admission
 Mild Ref Ref  
 Moderate 1.75 (0.62–4.93) 2.17 (0.72–6.57) 0.171
 Severe 3.62 (0.96–13.64) 4.68 (1.12–19.55) 0.034
  1. aOR: adjusted odd ratios; IgM: immunoglobulin M; MP: Mycoplasma pneumoniae; OR: odds ratio; PCR: polymerase chain reaction; Ref: reference
  2. a*Adjusted for age, sex, macrolide resistance of MP, and duration between symptom onset and performance date of MP-specific IgM test
  3. b*Poor response includes slow response, no response and progression to stepwise treatment for MP pneumonia